H. pylori Infection: Eradication Therapy, Urea Breath Testing & Gastric Cancer Prevention

Helicobacter pylori is a microaerophilic bacterium uniquely adapted to survive gastric acidity through abundant urease activity, flagellar motility, and tight adherence to epithelial cells. Persistent infection produces a chronic inflammatory infiltrate in the mucosa—histologically gastritis—that disrupts mucosal defence, perturbs acid secretion over time, and permits ulcer formation when NSAIDs, smoking, or host vulnerability coincide.

Virulence factors such as the cag pathogenicity island and the CagA oncoprotein help explain why some hosts develop aggressive inflammation and higher subsequent gastric cancer risk while others remain minimally symptomatic. Colonisation usually begins in childhood and, without eradication, often persists for decades, providing a long window for mucosal remodeling along the Correa cascade toward intestinal metaplasia in susceptible individuals.

Most colonised persons never seek care. When symptoms occur, they overlap heavily with functional dyspepsia and gastroesophageal reflux disease (GERD): burning epigastric pain, heartburn, post-prandial fullness, early satiety, belching, nausea, and vomiting. Classically, ulcer-type pain may wax and wane with meals depending on gastric versus duodenal localisation, but this pattern lacks specificity.

Haemorrhage may manifest only as fatigue from chronic blood loss—think unexplained microcytic anaemia with low ferritin—or acute hemodynamic collapse with little prodrome. Immigrants from high-prevalence regions and close contacts of infected household members warrant a lower threshold for targeted testing when presentations drag on beyond eight weeks.

Infection is acquired principally in childhood through interpersonal transmission—fecal–oral, gastric–oral, oral–oral, and contaminated water remain implicated routes depending on setting. Crowded housing, limited sanitation, and higher community prevalence amplify acquisition odds.

Progression cofactors

• Long-term NSAID or aspirin use synergises with H. pylori to erode mucosa.
• Tobacco delays ulcer healing and compounds malignancy risk.
• Dietary patterns high in salted or smoked foods parallel elevated gastric cancer incidence in epidemiologic datasets.
• Host genetics and bacterial virulence strains modulate inflammatory intensity.

Clinical assessment

Begin with alarm-feature screening: hemodynamic stability, haemoglobin trajectory, weight change, dysphagia, persistent vomiting, palpable mass, and age-appropriate cancer anxiety. Stable uninvestigated dyspepsia in younger patients without red flags may proceed along non-invasive “test-and-treat” pathways endorsed by dyspepsia guidelines; alarm findings mandate urgent endoscopy rather than empiric eradication alone.

Non-invasive testing

• Urea breath testing (UBT): Detects urease activity—high specificity when washout rules are respected.
• Stool antigen (monoclonal): Convenient for primary diagnosis and eradication follow-up with similar washout caveats.
• Serology: Useful only in selected prevalence contexts; cannot distinguish cured from active infection—avoid for test-of-cure.

Invasive endoscopic methods

When esophagogastroduodenoscopy is performed for bleeding or alarm symptoms, rapid urease testing, histology, culture, and PCR from biopsies provide diagnosis and can unlock antibiotic susceptibility panels—critical as clarithromycin and fluoroquinolone resistance climbs.

Laboratory adjuncts

Macrocytic or microcytic anaemia panels, liver function tests during eradication (especially if hepatitis suspected), and renal dosing checks for metronidazole or amoxicillin adjustments align with safe antimicrobial stewardship.

1. Triage alarm features. Bleeding, obstruction, or worrying systemic findings → urgent ED assessment and likely endoscopy.
2. Medicine reconciliation. Map PPIs, antibiotics, bismuth—determine whether to pause agents before diagnostic UBT/stool (often ~2 weeks off PPI, ~4 weeks off antibiotics) when deferral is safe.
3. Select assay. UBT or monoclonal stool antigen for ambulatory diagnosis; endoscopic biopsy when indications exist.
4. Treat deliberately. Choose fourteen-day empiric regimen per local resistance data; pair with high-quality acid suppression—often omeprazole or equivalent PPI dosed to maximise antibiotic bioavailability.
5. Educate + safeguard. Counsel on adherence, alcohol avoidance with nitroimidazoles, hypersensitivity reporting, and contraception nuances where relevant.
6. Confirm eradication. Breath or stool testing ≥4 weeks post-antibiotics after PPI washout; pursue salvage therapy if positive.

↔On a small screen, swipe or scroll sideways to see the full table.

Eradication therapy combines potent acid suppression with two or more antibiotics (sometimes plus bismuth) to overcome antimicrobial resistance and biofilm-like niches. North American guidance published in 2024 recommends fourteen-day bismuth quadruple therapy as preferred empiric first-line therapy when susceptibility is unknown, reflecting rising clarithromycin resistance; rifabutin-based triple therapy or potassium-competitive acid blocker dual therapy appears when penicillin allergy or local formulary constraints apply.

Representative regimens (follow local protocols)

↔On a small screen, swipe or scroll sideways to see the full table.

Paired proton pump inhibition maintains intragastric pH in a range that improves antibiotic efficacy—agents such as omeprazole remain anchors unless protocols specify alternate PPI dosing.

Special populations

• Pregnancy: defer elective testing/treatment to maternal–fetal medicine & gastroenterology unless compelling ulcer bleeding—the teratogenic profile of several eradication components limits empiric cocktail use.
• Severe hepatic or renal impairment: adjust nitroimidazole intervals per monograph; involve pharmacy.
• Penicillin allergy: avoid amoxicillin-containing kits; bismuth quadruple or guided therapy replaces beta-lactam options.

• Anchor counselling around adherence—partial courses fuel resistance and falsely reassure practitioners.
• Use teach-back to confirm patients understand urea breath testing washout rules before clinic appointments.
• Pair each antimicrobial dose with safe medication administration checks; involve interpreters when literacy barriers threaten adherence.
• Flag QT-prolonging co-medications when macrolides or fluoroquinolones appear on charts.
• Escalate to gastroenterology early if recurrent dyspepsia after two eradication attempts—culture/PCR susceptibility changes salvage choices.

• Acute or chronic upper gastrointestinal bleeding with hemodynamic compromise.
• Gastric outlet obstruction from prepyloric ulcer scarring.
• Iron deficiency anaemia from occult blood loss.
• Association with immune thrombocytopenia in some cohorts—coordinate testing when unexplained thrombocytopenia coexists.
• Gastric adenocarcinoma and gastric MALT lymphoma across decades of inflammation.

There is no vaccine. Prevention emphasises sanitation, safe drinking water, household hygiene, judicious NSAID prescribing with gastroprotection or eradication when infection is identified, and smoking cessation counselling. Test-and-treat strategies for dyspepsia can interrupt onward transmission within families once index cases complete therapy—trace contacts when local public health guidance supports it.

Modern fourteen-day optimised regimens eradicate infection in most treatment-naïve patients but population-level success rates fall as resistance rises—documented test-of-cure is the only reliable outcome metric. Successful eradication dramatically lowers ulcer relapse risk and contributes to gastric cancer prevention alongside dietary modification in high-burden regions. Functional dyspepsia symptoms may nonetheless persist in a subset despite clearance, requiring ongoing symptom-directed care rather than repeated blind antibiotics.

Medication teaching that sticks

Translate regimen complexity into pill organisers, translated pictograms, and explicit warnings about alcohol with nitroimidazoles. Highlight that dark stools on bismuth can mimic bleeding—patients should seek review if stools become tarry, foul, or accompanied by presyncope.

Documentation cues

Record symptom onset, bleeding descriptors, prior macrolide exposure, antimicrobial allergies, and education timestamp—these variables steer guideline-concordant regimen selection during handovers.

While activating massive transfusion or urgent endoscopy pathways, continue serial observations, secure large-bore access per protocol, reverse anticoagulation only under orders, and avoid masking instability with casual PPI doses alone.

These NCLEX-style clinical judgment practice items focus on the nursing priorities for this condition — recognise cues, escalate red flags, take safe action and evaluate outcomes (NCSBN Clinical Judgment Measurement Model) — through Priority FIRST, SATA, deterioration cues, multi-patient triage, ordered response, matrix matching and cloze drops on the topic of eradication therapy, urea breath testing washouts, bleeding escalation and antibiotic adverse effects—mirroring the Clinical Judgment Measurement Model emphasis on safe sequencing during infectious gastroenterology care.